The Potential of the Biofield Energy Treated Novel Proprietary Test Formulation on Organs Specific Biomarkers

Journal: Current Trends in Pharmacology and Clinical Trials PDF  

Published: 21-Jun-19 Volume: 2 Issue: 3

ISSN: 2462-0848

Authors: Arul I, Trivedi MK, Branton A, Trivedi D, Nayak G, Mondal SC and Jana S

Citation: Arul I, et al. The Potential of the Biofield Energy Treated Novel Proprietary Test Formulation on Organs Specific Biomarkers. Curr Trends Pharma Clinical Trials 2019, 2(3): 180021.

  • 49 Views
  • Downloads

Abstract

The study was investigated to find out the impact of the Biofield Energy Treated test formulation on the function of vital organs viz. bones, heart, liver, lungs, and brain in various cell-based assays. The test formulation and the cell media was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Inthirani Arul, Canada and was labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the test formulation was safe and non-toxic in nature in six different cells. The Biofield Energy Treated medium (BT-Med) + untreated test item (UT-TI) group showed 97.9% and 88.9% restoration of cell viability at 10 and 25 μg/mL, respectively as compared to the UT-Med + UT-TI group in human cardiac fibroblasts cells (HCF). Moreover, BT-Med + BT-TI group showed 62.8% and 86.2% restoration of cell viability at 1 and 63 μg/mL, respectively in human hepatoma cells (HepG2) compared to untreated. Furthermore, 125.6% (at 0.1 μg/mL) and 94.8% (at 63 μg/mL) restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by UT-Med + BT-TI and BT-Med + UT-TI groups, respectively compared to the untreated.

The alkaline phosphatase (ALP) level was significantly increased by 81.8%, 83.9%, and 83.2% in the UT-Med + BT-TI, BTMed + UT-TI, and BT-Med + BT-TI groups, respectively at 50 μg/mL in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by 1430% (at 0.1 μg/mL), 332.6% (at 1 μg/mL), and 265% (at 0.1 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 69% (at 1 μg/mL), 100.9% (at 0.1 μg/mL), and 76.9% (at 25 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 44.4% (at 0.1 μg/mL), 63.9% (at 10 μg/mL), and 84.9% (at 1 μg/mL) in the UT-Med + BT-TI, BT-Med + UTTI, and BT-Med + BT-TI groups, respectively compared to untreated in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 35.1% and 78.3% in the UT-Med + BT-TI and BTMed + BT-TI groups, respectively at 1 μg/mL compared to untreated in A549 cells.

Serotonin level was significantly increased by 71.6%, 82.8%, and 104.8% in the BT-Med + BT-TI group at 1, 10, and 25 μg/mL, respectively as compared to untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 253.5% (at 1 μg/mL) and 270.3% (at 50 μg/mL) in the BT Med + BT-TI group; while 235.2% at 10 μg/mL in the BT-Med + UT-TI group as compared to the untreated in MG-63 cells. Overall, these results suggest that Biofield Treated test formulation significantly improved the relevant bones, heart, liver, lungs, and brain-related biomarkers. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect®) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones. Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as coronary artery disease, heart attack, heart failure, arrhythmias, congenital heart disease, cirrhosis, cardiomyopathy, liver cancer, Wilson disease, hemochromatosis, pneumonia, asthma, chronic bronchitis, emphysema, osteoporosis, cystic fibrosis, etc.

Conclusion

The study findings showed that the tested novel test formulation was safe and non-toxic based on MTT cell viability assay in six tested cells. The treatment group like BT-Med + UT-TI showed 97.9% and 88.9% restoration of cell viability at 10 and 25 μg/mL, respectively in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, the BT-Med + BT-TI group showed 62.8% and 86.2% restoration of cell viability at 1 and 63 μg/mL, respectively in human hepatoma cells (HepG2) compared to the untreated group. Additionally, the UT-Med + BT-TI and BT-Med + UT-TI groups showed 125.6% (at 0.1 μg/mL) and 94.8% (at 63 μg/mL) restoration of cell viability, respectively in adenocarcinomic human alveolar basal epithelial cells (A549) compared to the untreated group. Alkaline phosphatase (ALP) activity was significantly increased by 83.9% in the BT-Med + UT TI group at 50 μg/mL in human bone osteosarcoma cells (MG-63). Moreover, ALP activity was significantly increased by 1430% (at 0.1 μg/mL), 332.6% (at 1 μg/mL), and 265% (at 0.1 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively than untreated group.

The percent protection of HCF cells (decreased of LDH activity) was significantly increased by 100.9% (at 0.1 μg/mL) in the BT-Med + UT-TI group compared to the untreated group in HCF cells. The percent protection of HepG2 cells (decreased of ALT activity) was significantly increased by 84.9% (at 1 μg/mL) in the BT-Med + BT-TI group compared to the untreated group in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 78.3% in the BT-Med + BT-TI group at 1 μg/mL compared to the untreated group in A549 cells. The serotonin level was significantly increased by 82.8% and 104.8% at 10 and 25 μg/mL, respectively in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively compared to the untreated group in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptors (VDRs) level was significantly increased by 253.5% (at 1 μg/mL) and 270.3% (at 50 μg/mL) in the BT-Med + BT-TI group; while 235.2% at 10 μg/mL in the BT-Med + UT-TI as compared to the untreated in MG-63 cells compared to

the untreated group in MG-63 cells. In conclusion, The Biofield Energy Treatment significantly improved heart, liver, bones, neuronal, and lungs parameters and also protected cardiomyocyte, hepatocyte, osteocytes, pneumocyte, and nerve cells from oxidative damage induced by tert-butyl hydroperoxide (t-BHP). Thus, results suggested that Biofield Energy Treatment can be used as a complementary and alternative treatment for the prevention of various types of cardiac disorders (peripheral artery disease, high blood pressure, congenital heart disease, stroke, congestive heart failure, rheumatic heart disease, carditis, valvular heart disease, thromboembolic disease, and venous thrombosis, etc.), hepatic disorders (cirrhosis, Wilson disease, liver cancer, hemochromatosis), and lungs disorders (Asthma, Emphysema, Chronic bronchitis, Pneumonia, Cystic fibrosis).

Further, it can be useful to improve cell-to-cell messaging, normal cell growth and differentiation, cell cycling and proliferation, neurotransmission, skin health, hormonal balance, immune and cardiovascular functions. Moreover, it can also be utilized in organ transplants (i.e., liver, kidney, and heart transplants), , aging, hormonal imbalance and various inflammatory and immune-related disease conditions like Alzheimer’s Disease (AD), Dermatitis, Asthma, Ulcerative Colitis (UC), Hashimoto Thyroiditis, Pernicious Anemia, Sjogren Syndrome, Aplastic Anemia, Multiple Sclerosis, Hepatitis, Graves’ Disease, Irritable Bowel Syndrome (IBS), Dermatomyositis, Diabetes, Myasthenia Gravis, Atherosclerosis, Parkinson’s Disease, Systemic etc. to Lupus Erythematosus (SLE), stress, improve overall health and Quality of Life.